In another study, lower baseline sPD-L1 and higher post-treatment VEGF levels were both independently associated with increased and reduced PFS, respectively, in NSCLC patients treated with PD-L1 inhibitors combined with anti-angiogenetic therapy [50]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.